Literature DB >> 20633193

Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009).

Shigeki Arii1, Michio Sata, Michiie Sakamoto, Mitsuo Shimada, Takashi Kumada, Shuichiro Shiina, Tatsuya Yamashita, Norihiro Kokudo, Masatoshi Tanaka, Tadatoshi Takayama, Masatoshi Kudo.   

Abstract

Hepatocellular carcinoma (HCC) is responsible for approximately 600 000-700 000 deaths worldwide. It is highly prevalent in the Asia-Pacific region and Africa, and is increasing in Western countries. The evidence-based guideline for HCC in Japan was published in 2005 and revised in 2009. Apart from this guideline, a consensus-based practice manual proposed by the HCC expert panel of the Japan Society of Hepatology (JSH), which reflects widely accepted daily practice in Japan, was published in 2007. At the occasion of the 45th Annual meeting of the JSH in Kobe 4-5 June 2009, a consensus meeting of HCC was held. Consensus statements were createdbased on 67% agreement of 200 expert members.This article describes the up-to-date consensus statements which largely reflect the real world HCC practice in Japan. We believe readers of this article will gain the newest knowledge and deep insight on the management of HCC proposed by consensus of the HCC expert members of JSH.

Entities:  

Year:  2010        PMID: 20633193     DOI: 10.1111/j.1872-034X.2010.00673.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  44 in total

1.  Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma.

Authors:  Yukinori Imai; Taku Chikayama; Manabu Nakazawa; Kazuhiro Watanabe; Satsuki Ando; Yoshie Mizuno; Kiyoko Yoshino; Kayoko Sugawara; Kazuhiro Hamaoka; Kenji Fujimori; Mie Inao; Nobuaki Nakayama; Masashi Oka; Sumiko Nagoshi; Satoshi Mochida
Journal:  J Gastroenterol       Date:  2011-10-06       Impact factor: 7.527

2.  Incidence for progression of hypervascular HCC in hypovascular hepatic nodules showing hyperintensity on gadoxetic acid-enhanced hepatobiliary phase in patients with chronic liver diseases.

Authors:  Megumi Matsuda; Takaharu Tsuda; Shinji Yoshioka; Shigetoshi Murata; Hiroaki Tanaka; Masashi Hirooka; Yoichi Hiasa; Teruhito Mochizuki
Journal:  Jpn J Radiol       Date:  2014-05-24       Impact factor: 2.374

3.  Advanced hepatocellular carcinoma responds to MK615, a compound extract from the Japanese apricot "Prunus mume".

Authors:  Takashi Hoshino; Hitoshi Takagi; Atsushi Naganuma; Eri Koitabashi; Sanae Uehara; Naomi Sakamoto; Tomohiro Kudo; Ken Sato; Satoru Kakizaki
Journal:  World J Hepatol       Date:  2013-10-27

Review 4.  Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age.

Authors:  Koji Miyahara; Kazuhiro Nouso; Kazuhide Yamamoto
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

5.  The expression of transporter OATP2/OATP8 decreases in undetectable hepatocellular carcinoma by Gd-EOB-MRI in the explanted cirrhotic liver.

Authors:  Masaaki Hidaka; Mitsuhisa Takatsuki; Sadayuki Okudaira; Akihiko Soyama; Izumi Muraoka; Takayuki Tanaka; Izumi Yamaguchi; Takanobu Hara; Hisamitsu Miyaaki; Tatsuki Ichikawa; Tomayoshi Hayashi; Ichiro Sakamoto; Kazuhiko Nakao; Tamotsu Kuroki; Takashi Kanematsu; Susumu Eguchi
Journal:  Hepatol Int       Date:  2012-06-24       Impact factor: 6.047

Review 6.  Current status of hepatocellular carcinoma treatment in Japan: transarterial chemoembolization.

Authors:  Osamu Matsui
Journal:  Clin Drug Investig       Date:  2012-08-08       Impact factor: 2.859

7.  Clinicopathologic features and risk factors for extrahepatic recurrences of hepatocellular carcinoma after curative resection.

Authors:  Toshiya Ochiai; Hisashi Ikoma; Kazuma Okamoto; Yukihito Kokuba; Teruhisa Sonoyama; Eigo Otsuji
Journal:  World J Surg       Date:  2012-01       Impact factor: 3.352

8.  Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization.

Authors:  Takuma Arai; Akira Kobayashi; Ayumi Ohya; Masaaki Takahashi; Takahide Yokoyama; Akira Shimizu; Hiroaki Motoyama; Norihiko Furusawa; Tsuyoshi Notake; Noriyuki Kitagawa; Hiroshi Sakai; Hiroshi Imamura; Masumi Kadoya; Shin-Ichi Miyagawa
Journal:  Int J Clin Oncol       Date:  2013-11-12       Impact factor: 3.402

Review 9.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

10.  Comparison of percutaneous radiofrequency ablation and CyberKnife(®) for initial solitary hepatocellular carcinoma: A pilot study.

Authors:  Kazue Shiozawa; Manabu Watanabe; Takashi Ikehara; Yasushi Matsukiyo; Michio Kogame; Yui Kishimoto; Yusuke Okubo; Hiroyuki Makino; Nobuhiro Tsukamoto; Yoshinori Igarashi; Yasukiyo Sumino
Journal:  World J Gastroenterol       Date:  2015-12-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.